ES8301197A1 - Un procedimiento para la preparacion de tioeteres. - Google Patents

Un procedimiento para la preparacion de tioeteres.

Info

Publication number
ES8301197A1
ES8301197A1 ES501496A ES501496A ES8301197A1 ES 8301197 A1 ES8301197 A1 ES 8301197A1 ES 501496 A ES501496 A ES 501496A ES 501496 A ES501496 A ES 501496A ES 8301197 A1 ES8301197 A1 ES 8301197A1
Authority
ES
Spain
Prior art keywords
carbon atoms
residue
alkyl
amino acid
image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES501496A
Other languages
English (en)
Other versions
ES501496A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of ES501496A0 publication Critical patent/ES501496A0/es
Publication of ES8301197A1 publication Critical patent/ES8301197A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Electrical Connectors (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE TIOETERES DE FORMULA (I); DONDE X ES O, S O NR ; R S ES UN RESTO DE CUALQUIER AGENTE BIOLOGICAMENTE ACTIVO R SH; R SIGNIFICA ALQUILO DE CADENA LINEAL O RAMIFICADA DE 1 A 20 ATOMOS DE CARBONO, ARILO, CICLOALQUILO, ALQUENILO, ARALQUILO, ALQUINILARILO O CARBOXIALQUILO; R ES HIDROGENO, ACILO INFERIOR, CIANO O CARBONILO; R ES HIDROGENO O ALQUILO INFERIOR; Y SUS SALES NO TOXICAS FARMACEUTICAMENTE ACEPTABLE CONSISTE EN HACER REACCIONAR UN MERCAPTANO DE FORMULA R <024>SH, CO UN COMPUESTO DE FORMULA (II), EN DONDE Z REPRESENTA UN GRUPO SALIENTE Y R , R , R Y X TIENEN LOS SIGNIFICADOS YA INDICADOS, EN PRESENCIA O AUSENCIA DE 2-4 EQUIVALENTES DE UNA BASE Y EN PRESENCIA DE UN DISOLVENTE ADECUADO. >DE APLICACION EN FARMACIA COMO AGENTE BIOLOGICAMETE ACTIVO.
ES501496A 1980-04-21 1981-04-20 Un procedimiento para la preparacion de tioeteres. Expired ES8301197A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14198180A 1980-04-21 1980-04-21

Publications (2)

Publication Number Publication Date
ES501496A0 ES501496A0 (es) 1982-12-01
ES8301197A1 true ES8301197A1 (es) 1982-12-01

Family

ID=22498074

Family Applications (1)

Application Number Title Priority Date Filing Date
ES501496A Expired ES8301197A1 (es) 1980-04-21 1981-04-20 Un procedimiento para la preparacion de tioeteres.

Country Status (10)

Country Link
US (1) US4443435A (es)
EP (1) EP0038541B1 (es)
JP (1) JPS572252A (es)
AT (1) ATE21388T1 (es)
DE (1) DE3175100D1 (es)
DK (1) DK172081A (es)
ES (1) ES8301197A1 (es)
GR (1) GR75219B (es)
IE (1) IE52017B1 (es)
PT (1) PT72877B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75219B (es) * 1980-04-21 1984-07-13 Merck & Co Inc
JPS57183778A (en) * 1981-04-30 1982-11-12 Nippon Synthetic Chem Ind Co Ltd:The S-(3-phthalidyl)-l-cysteine and its preparation
US4454065A (en) * 1982-05-18 1984-06-12 Smithkline Beckman Corporation Oligopeptide prodrugs
DK302883D0 (da) * 1983-06-30 1983-06-30 Hans Bundgaard Allopurinol prodrugs
CS249576B1 (en) * 1984-12-22 1987-04-16 Antonin Cerny 6-purinyl n-(2-chlorethyl)carbamate and thiocarbamate and method of their production
WO1986004929A1 (en) 1985-02-22 1986-08-28 Kawasaki Steel Corporation Process for producing unidirectional silicon steel plate with extraordinarily low iron loss
US5203928A (en) * 1986-03-25 1993-04-20 Kawasaki Steel Corporation Method of producing low iron loss grain oriented silicon steel thin sheets having excellent surface properties
JPH0615694B2 (ja) * 1987-04-17 1994-03-02 川崎製鉄株式会社 方向性けい素鋼板の鉄損低減方法
DE3889600T2 (de) * 1987-08-01 1994-09-01 Kawasaki Steel Co Kornorientierte Elektrobleche mit sehr geringen Eisenverlusten und Verfahren zum Herstellen dieser Bleche.
US5120740A (en) * 1989-11-03 1992-06-09 Wisconsin Alumni Research Foundation Prodrugs of 6-mercaptopurine and 6-thioguanine
JPH0723511B2 (ja) * 1989-12-07 1995-03-15 新日本製鐵株式会社 一方向性電磁鋼帯の処理装置
KR0182802B1 (ko) * 1993-01-12 1999-04-01 다나카 미노루 극히 낮은 철손을 갖는 일방향성 전자강판 및 그 제조방법
US5823679A (en) * 1993-09-17 1998-10-20 Omega Engineering, Inc. Method and apparatus for measuring temperature including aiming light
FR2773214B1 (fr) 1996-12-11 2002-05-31 Omega Engineering Procede et dispositif pour la mesure par infrarouge de la temperature d'une surface
DE69810852T2 (de) * 1997-07-17 2003-06-05 Kawasaki Steel Co Kornorientiertes Elektrostahlblech mit ausgezeichneten magnetischen Eigenschaften und dessen Herstellungsverfahren
US7399369B2 (en) 2001-07-16 2008-07-15 Nippon Steel Corporation Ultra-high magnetic flux density grain-oriented electrical steel sheet excellent in iron loss at a high magnetic flux density and film properties and method for producing the same
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
US20060008520A1 (en) * 2004-04-01 2006-01-12 Lerner E I Delayed release formulations of 6-mercaptopurine
WO2008062853A1 (fr) 2006-11-22 2008-05-29 Nippon Steel Corporation Feuille d'acier électromagnétique à orientation unidirectionnelle de grains, ayant une excellente adhésion de film, et son procédé de fabrication
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
EP2110130A1 (en) * 2008-04-18 2009-10-21 Teva Pharmaceutical Industries Ltd. Pharmaceutical use of 6-mercaptopurine
MX2012014567A (es) 2010-06-29 2013-02-12 Jfe Steel Corp Placa de acero magnetico orientado y metodo de produccion de la misma.
JP5927754B2 (ja) 2010-06-29 2016-06-01 Ｊｆｅスチール株式会社 方向性電磁鋼板およびその製造方法
JP5593942B2 (ja) 2010-08-06 2014-09-24 Ｊｆｅスチール株式会社 方向性電磁鋼板およびその製造方法
JP5853352B2 (ja) 2010-08-06 2016-02-09 Ｊｆｅスチール株式会社 方向性電磁鋼板およびその製造方法
MX335959B (es) 2010-08-06 2016-01-05 Jfe Steel Corp Lamina de acero electrico de grano orientado y metodo para la fabricacion de la misma.
JP5998424B2 (ja) 2010-08-06 2016-09-28 Ｊｆｅスチール株式会社 方向性電磁鋼板
WO2013099160A1 (ja) 2011-12-26 2013-07-04 Ｊｆｅスチール株式会社 方向性電磁鋼板
WO2013099219A1 (ja) 2011-12-27 2013-07-04 Ｊｆｅスチール株式会社 方向性電磁鋼板の鉄損改善装置
EP2799574B1 (en) 2011-12-27 2017-02-01 JFE Steel Corporation Grain-oriented electrical steel sheet
RU2578296C2 (ru) 2011-12-28 2016-03-27 ДжФЕ СТИЛ КОРПОРЕЙШН Текстурированный лист из электротехнической стали и способ снижения потерь в железе
US10804015B2 (en) 2011-12-29 2020-10-13 Posco Electrical steel sheet and method for manufacturing the same
KR101636191B1 (ko) 2012-04-26 2016-07-04 제이에프이 스틸 가부시키가이샤 방향성 전기 강판 및 그 제조 방법
JP5971157B2 (ja) 2013-03-11 2016-08-17 Ｊｆｅスチール株式会社 塗布装置および塗布方法
JP5668795B2 (ja) 2013-06-19 2015-02-12 Ｊｆｅスチール株式会社 方向性電磁鋼板およびそれを用いた変圧器鉄心
EP3048180B2 (en) 2013-09-19 2022-01-05 JFE Steel Corporation Grain-oriented electrical steel sheet, and method for manufacturing same
JP6215673B2 (ja) 2013-11-29 2017-10-18 東芝産業機器システム株式会社 ベクトル磁気特性制御材、および、鉄心
KR101639920B1 (ko) 2014-12-26 2016-07-15 주식회사 포스코 방향성 전기강판의 자구미세화 장치 및 그 방법
EP3362053A4 (en) 2015-10-16 2019-04-17 Hadasit Medical Research Services and Development Ltd. TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE
RU2717034C1 (ru) 2017-02-28 2020-03-17 ДжФЕ СТИЛ КОРПОРЕЙШН Текстурированная электротехническая листовая сталь и способ ее производства
WO2022113517A1 (ja) 2020-11-27 2022-06-02 Ｊｆｅスチール株式会社 方向性電磁鋼板およびその製造方法
CN115724824B (zh) * 2021-09-01 2024-03-15 四川大学 3-(酰胺烷硫基)苯酞类化合物、其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852506A (en) * 1955-10-31 1958-09-16 American Cyanamid Co Method of preparing aminodeoxyglycosidopurines
US2844576A (en) * 1955-11-22 1958-07-22 American Cyanamid Co Preparation of purines
BE733669A (es) * 1968-06-04 1969-11-27
US3915958A (en) * 1972-05-22 1975-10-28 Icn Pharmaceuticals 6-Substituted purine nucleotides
JPS49117479A (es) * 1973-05-30 1974-11-09
US3957803A (en) * 1975-01-06 1976-05-18 Interx Research Corporation Certain transient pro-drug forms of phenylbutazone
US4061753A (en) * 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
US4275064A (en) * 1976-02-06 1981-06-23 Interx Research Corporation Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents
US4235887A (en) * 1977-04-13 1980-11-25 The Upjohn Company Process for therapeutic treatment
JPS5589257A (en) * 1978-12-22 1980-07-05 Kanebo Ltd New easily-absorbable sulfur-containing prodrug of non- steroidal antiphlogistic, and their drug compositions
NZ196349A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
GR75219B (es) * 1980-04-21 1984-07-13 Merck & Co Inc

Also Published As

Publication number Publication date
ES501496A0 (es) 1982-12-01
EP0038541A1 (en) 1981-10-28
EP0038541B1 (en) 1986-08-13
IE810869L (en) 1982-10-21
PT72877B (en) 1983-03-29
DE3175100D1 (en) 1986-09-18
ATE21388T1 (de) 1986-08-15
PT72877A (en) 1981-05-01
DK172081A (da) 1981-10-22
US4443435A (en) 1984-04-17
JPS572252A (en) 1982-01-07
IE52017B1 (en) 1987-05-27
GR75219B (es) 1984-07-13
JPH0226630B2 (es) 1990-06-12

Similar Documents

Publication Publication Date Title
DE3175100D1 (en) Novel prodrugs of biologically active agents containing mercapto groups, process for preparing and therapeutically effective composition containing the same
JPS5671074A (en) 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
ES8401941A1 (es) Procedimiento para la preparacion de derivados de acido espiro (4.(3+n))-2-aza-3carboxilico.
ES8609247A1 (es) Un procedimiento para la preparacion de derivados del indol
DE69025104D1 (de) Thiazolderivate, Verfahren zur Ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
ES469952A1 (es) Un procedimiento para la preparacion de aminoalquiltiofenos
DK151627C (da) Analogifremgangsmaade til fremstilling af terapeutisk virksomme 4-(fenylalkenyl)-imidazolderivater eller ugiftige, farmaceutisk acceptable syreadditionssalte deraf.
ES8107201A1 (es) Un procedimiento para la preparacion de derivados de morfo- lina
ES8301927A1 (es) Procedimiento de preparacion de acidos azabiciclohexano car-boxilicos y de sus sales
ES8801826A1 (es) Procedimiento para preparar derivados de 1,3-di-azolil-2-propanol con propiedades antifungales
CA2174544A1 (en) Method for using pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines as adrenergic agents
ES8609225A1 (es) Un procedimiento para preparar un derivado de semicarbazida
ES8801266A1 (es) Un procedimiento para preparar nuevos compuestos heterociclicos condensados con benceno
ES495105A0 (es) Un metodo de preparar derivados de fenil-piperazina farma- ceuticamente activos
KR890008101A (ko) β-아드레날린성 애고니스트
ES8404320A1 (es) Procedimiento para la obtencion de derivados n-oxalilicos de n-metilcarbamatos
EP0318859A3 (en) N-substituted mercaptopropanamide derivatives
ES8405020A1 (es) Un procedimiento para la preparacion de derivados de fosfolipidos.
ES8801227A1 (es) Procedimiento para preparar derivados de benzazol
ES8604122A1 (es) Procedimiento de preparacion de eteres oximas basicos y de sus sales de adicion acidas farmaceuticamente aceptables
ES8104242A1 (es) Un procedimiento para la preparacion de nuevos derivados de hidantoina.
ES476232A1 (es) Procedimiento para la obtencion de derivados del fosfonilu- reidobenceno.
JPS54144333A (en) Tetrapeptide derivative
IL70103A0 (en) Semicarbazides,their preparation and pharmaceutical compositions containing them
GB2014562A (en) Cephalosporin analogues and processes for their preparation thereof

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970303